1. Home
  2. Labeler Index
  3. Biogen Inc.
  4. 64406-019
  5. Product Images: Byooviz

Product Images Byooviz

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 24 images provide visual information about the product associated with Byooviz NDC 64406-019 by Biogen Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure - sb11 01

Figure - sb11 01

Figure - sb11 02

Figure - sb11 02

Figure - sb11 03

Figure - sb11 03

Figure - sb11 04

Figure - sb11 04

Figure - sb11 05

Figure - sb11 05

Figure 1 - sb11 06

Figure 1 - sb11 06

This is a chart showing the mean change in visual acuity, measured in letters, over a period of 24 months for AMD-2. The data is presented in a table with values ranging from -10 to 15. There is no indication of the units used for the measurement.*

Figure - sb11 07

Figure - sb11 07

Figure - sb11 08

Figure - sb11 08

Figure - sb11 09

Figure - sb11 09

Figure - sb11 10

Figure - sb11 10

Figure 2 - sb11 11

Figure 2 - sb11 11

Figure - sb11 12

Figure - sb11 12

Figure - sb11 13

Figure - sb11 13

Figure 3 - sb11 14

Figure 3 - sb11 14

Figure - sb11 15

Figure - sb11 15

Figure - sb11 16

Figure - sb11 16

Figure 4 - sb11 17

Figure 4 - sb11 17

This is a graph showcasing the distribution of the number of injections received by patients using the drug NB0. The horizontal axis shows the range of the number of injections administered, while the vertical axis shows the percentage of patients who received that specific number of injections. The mean number of injections administered is 10.3.*

Figure 5 - sb11 18

Figure 5 - sb11 18

Figure - sb11 19

Figure - sb11 19

Figure - sb11 20

Figure - sb11 20

Figure - sb11 21

Figure - sb11 21

Figure - sb11 22

Figure - sb11 22

Figure 6 - sb11 23

Figure 6 - sb11 23

This appears to be a table with some data related to a study involving a Ranibizumab Group 1, Ranibizumab Group 2, and a Control group. The numerals 15, 124, and 3 are likely related to some metrics used in the study, but not enough context is present to determine their exact meaning. The text "Mean change in BCVA from baseline" suggests that the study may be related to visual acuity, and "Letters ETDRS" could refer to a common measurement tool for grading visual impairment. Overall, without additional information, it is unclear what specific insights or conclusions can be drawn from this text.*

PRINCIPAL DISPLAY PANEL - 0.5 mg Vial Carton - sb11 24

PRINCIPAL DISPLAY PANEL - 0.5 mg Vial Carton - sb11 24

This is a description of a medicine called Byooviz. Byooviz is a 0.5mg single-dose vial, which contains ranibizumab-nuna. The vial is designed to deliver 0.05mL of 10mg/mL of ranibizumab-nuna aqueous solution, which includes 10mM histidine HCl, 10% a,a-trehalose dihydrate, and 0.01% polysorbate 20, and has a pH of 5.5. Byooviz is indicated for Neovascular (wet) age-related macular degeneration (AMD), Macular edema following retinal vein occlusion (RVO), Myopic choroidal neovascularization (CNV). The vial should be kept refrigerated and should be protected from light. The medicine is manufactured by Samsung Bioepis Co., Ltd., located in Incheon, Republic of Korea, and distributed by Biogen Inc.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.